ABRITIGA 250MG TABLETS

ABRITIGA 250mg Tablets are a prescription hormonal anticancer medicine containing abiraterone acetate, widely used in the treatment of metastatic prostate cancer and castration-resistant prostate cancer (CRPC). This oral therapy is an important part of advanced prostate cancer management, targeting hormone-driven tumor growth at its source.

Abiraterone acetate works by inhibiting androgen production in the adrenal glands, testes, and tumor tissue. By significantly lowering male hormone levels, ABRITIGA helps slow the growth and spread of prostate cancer cells and improves disease control. It is commonly prescribed alongside corticosteroids to enhance effectiveness and reduce treatment-related side effects.

ABRITIGA 250 mg tablets ensure consistent quality, safety, and therapeutic efficacy. This is a prescription-only oncology medicine intended for oral use and must be taken strictly under the supervision of a qualified oncologist. ABRITIGA provides a reliable and clinically proven option for long-term hormonal therapy in patients with advanced prostate cancer.

Product Features

• Hormonal prostate cancer therapy tablet
• Contains Abiraterone Acetate 250 mg
• Inhibits androgen biosynthesis effectively
• Used in metastatic and castration-resistant prostate cancer
• Oral tablet dosage form for convenient administration
• Often prescribed in combination with prednisone
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Reduces androgen (male hormone) production that fuels prostate cancer growth
• Slows the progression and spread of advanced prostate cancer cells
• Effective in metastatic and castration-resistant prostate cancer
• Improves treatment outcomes when used with prescribed corticosteroids